XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Restatement of comparatives
6 Months Ended
Dec. 31, 2022
Text block [abstract]  
Restatement of comparatives
Note 3. Restatement of comparatives
Correction of error
During the December 2022 review, the calculation of the EVT-801 asset and its contingent consideration was found to contain errors as discounting for the time value of money was not taken into account on initial recognition.
The contractual payments in relation to the milestones gave rise to a financial liability at acquisition. The cost of the intangible asset should comprise the initial payment plus an amount reflecting the fair value of the other contingent payments determined using a probability–weighted estimation. These values should be discounted to reflect the time value of money at the time of acquisition in April 2021. Management have utilised an Incremental Borrowing Rate of 6% to discount the future cash flows. The Incremental Borrowing Rate reflects the assumed credit rating of the Company.
The error resulted in a material overstatement of the EVT-801 asset and a corresponding overstatement of the liability at acquisition. The impact of this error is noted below with the restated balances disclosed in note 10,14 and 16:
 
 
    
30 June 2022
   
Increase/
(decrease)
   
30 June 2022
Restated
 
Intangibles - licensing agreement EVT-801
     10,857,763       (1,044,401     9,813,362  
Less Accumulated amortisation
     (1,049,555     133,641       (915,914
      
9,808,208
     
(910,760
)
 
   
8,897,448
 
       
Current contingent consideration EVT-801
     (758,840     —         (758,840
Non-Current contingent consideration EVT-801
     (7,588,405     546,996       (7,041,409
      
(8,347,245
)
 
   
546,996
     
(7,800,249
)
 
       
Net Assets
    
18,638,287
     
(363,764
)
 
   
18,274,523
 
Accumulated losses
     (68,253,627     (363,764     (68,617,391
Total equity
    
18,638,287
     
(363,764
)
 
   
18,274,523
 












Consolidated statement of profit and loss
  
31 December
2021
   
(Increase)/
Decrease
   
31 December
2021
Restated
 
Research and development expense (Amortisation)
     (11,029,851     41,776       (10,988,075
General and administrative expense (interest and foreign exchange impact)
     (2,261,366     (221,216     (2,482,582
Loss before tax
    
(13,338,382
)
 
   
(179,440
)
 
   
(13,517,822
)
 
Income tax benefit
     315,974       —         315,974  
Loss after tax
    
(13,022,408
)
 
   
(179,440
)
 
   
(13,201,848
)
 
       
Impact on basic and diluted earnings per share increase/(decrease) in earning per share
  
Cents
   
Cents
   
Cents
 
Basic loss for the year attributable to equity holders
     (9.864     (0.136     (10.000
Diluted loss for the year attributable to equity holders
     (9.864     (0.136     (10.000